apan's approval came despite a lack of a large clinical trial in the country, as the number of Covid-19 cases in the country remains significantly lower compared to other countries.
The Japanese government has approved its first vaccine against the Covid-19, kick-starting a massive rollout programme for the country of 126 million people.
Pfizer Inc.'s Covid-19 mRNA vaccine got the final approval for emergency use on Sunday from health minister Norihisa Tamura, two days after a government committee gave the shot its seal of approval, paving the way for inoculations to start as early as Wednesday, The Japan Times reported.
The vaccine approvals usually take a year or two, but the government shortened the review period to less than two months, scrapping the requirement for large, third phase clinical trials in Japan amid the mounting toll of the pandemic.
Japan, however, was still the last country among the Group of Seven nations to give it the OK as it required an additional clinical trial to be conducted on Japanese people to ensure safety.
The UK and the US approved the Pfizer shot, jointly developed by the US pharmaceutical giant and Germany's BioNTech SE, in December.
Late-stage trials of Pfizer's vaccine conducted on more than 43,000 participants, of which 5 per cent were Asian, in the US and five other countries have shown that it was 95 per cent effective in preventing Covid-19.
Japan's approval came despite a lack of a large clinical trial in the country, as the number of Covid-19 cases in the country remains significantly lower compared to other countries.
Tamura said Pfizer's clinical trial in Japan on 160 people age 20 to 85 has confirmed the vaccine's effectiveness in producing antibodies in line with the results from the large-scale trial conducted overseas.
The first shipments of Pfizer's vaccines arrived at Narita International Airport from Brussels on Friday, carrying vials for around 400,000 shots, according to Kyodo News. Japan has signed a contract to receive 144 million of Pfizer's vaccines, enough to inoculate 72 million people, by the end of 2021.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.